IL18 and small cell lung carcinoma: However, a promising approach yet to be proven clinically is based on engineering CAR-T cells to produce IL-12 and IL-18 and converting the environment to an acute inflammatory state, enhancing T-cell activation and tumour control, especially in macrophage-rich tumours like SCLC.